Patents by Inventor Birgit Wilding

Birgit Wilding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
    Publication number: 20230374021
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 10, 2023
    Publication date: November 23, 2023
    Inventors: Birgit WILDING, Dietrich BOESE, Harald ENGELHARDT, Julian FUCHS, Ralph NEUMUELLER, Mark PETRONCZKI, Dirk SCHARN, Matthias TREU
  • ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER
    Publication number: 20230227470
    Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: November 30, 2022
    Publication date: July 20, 2023
    Inventors: Joachim BROEKER, Jason ABBOTT, Jianwen CUI, Stephen W. FESIK, Julian FUCHS, Andreas GOLLNER, Lorenz HERDEIS, Tim HODGES, Andrew LITTLE, Andreas MANTOULIDIS, Jason PHAN, Juergen RAMHARTER, Dhruba SARKAR, Christian Alan Paul SMETHURST, Kevin SOKOL, Heinz STADTMUELLER, Qi SUN, Matthias TREU, Alex WATERSON, Birgit WILDING, Tobias WUNBERG
  • [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
    Publication number: 20230126204
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the R groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 1, 2021
    Publication date: April 27, 2023
    Inventors: Birgit WILDING, Dietrich BOESE, Harald ENGELHARDT, Julian FUCHS, Ralph NEUMUELLER, Mark PETRONCZKI, Dirk SCHARN, Matthias TREU
  • [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
    Publication number: 20230131720
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 1, 2021
    Publication date: April 27, 2023
    Inventors: Birgit WILDING, Dietrich BOESE, Harald ENGELHARDT, Julian FUCHS, Ralph NEUMUELLER, Mark PETRONCZKI, Dirk SCHARN, Matthias TREU
  • Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
    Patent number: 11608343
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: March 21, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Birgit Wilding, Dietrich Boese, Harald Engelhardt, Julian Fuchs, Ralph Neumueller, Mark Petronczki, Dirk Scharn, Matthias Treu
  • [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
    Publication number: 20210332054
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: April 6, 2021
    Publication date: October 28, 2021
    Inventors: Birgit WILDING, Dietrich BOESE, Harald ENGELHARDT, Julian FUCHS, Ralph NEUMUELLER, Mark PETRONCZKI, Dirk SCHARN, Matthias TREU
  • Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity
    Patent number: 10647678
    Abstract: The present invention relates to compounds of formula I wherein R, R4 and Q are each as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 pathway (HSF1 pathway). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: May 12, 2020
    Assignee: Cancer Research Technology Limited
    Inventors: Keith Jones, Matthew Cheeseman, Nicola Chessum, Elisa Pasqua, Lindsay Evans, Michael Tucker, Birgit Wilding, Ngai Yi Mok
  • QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY
    Publication number: 20180093955
    Abstract: The present invention relates to compounds of formula I wherein R, R4 and Q are each as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 pathway (HSF1 pathway). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: April 1, 2016
    Publication date: April 5, 2018
    Inventors: Keith Jones, Matthew Cheeseman, Nicola Chessum, Elise Pasqua, Lindsay Evans, Michael Tucker, Birgit Wilding, Ngal Yi Mok